List view / Grid view
Researchers have shown that Nilvadipine can slow the rate of cognitive decline in very early- and early-stage Alzheimer’s patients and have received funding to develop improved versions.
The FDA has approved Isturisa for Cushing’s disease treatment after it demonstrated significant efficacy in clinical trials.
Researchers have identified a tiny protein in scorpion venom that rapidly accumulates in joint cartilage to deliver arthritis drugs in a pre-clinical study.
The UK MHRA has announced that the approximately 3.5 million unlicensed erection pills seized last year are worth more than £10 million.
The DURYSTA ocular implant has been approved by the FDA to reduce intraocular pressure in open-angle glaucoma or ocular hypertension.
The UK MHRA has announced that Emerade 150 micrograms solution for injection is being recalled due to an error in one component of the auto-injector.
Stabilising DNA nanostructures using glutaraldehyde to tether an electrostatic PEGylated oligolysine net to the DNA enabled them to survive degradation in animal models.
Tests conducted by an online pharmacy has revealed high levels of NMDA in the diabetes drug metformin, prompting the company to press for a recall.
Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for $95.50 per share.
The UK’s Competition and Markets Authority (CMA) has fined four companies in because of anti-competitive practices in the supply of nortriptyline.
A new vaccine formulation has been created by researchers, which uses a peelable film during drying to preserve the medicine.
According to renowned data and analytics company GlobalData, India’s phased manufacturing programme will create significant opportunities for medical device manufacturers in India.
Thermo Fisher Scientific Inc has announced that it is to acquire QIAGEN N V for a value of €39 per share at current exchange rates.
Research has shown that the CAR-T therapies in development in Asia-Pacific will make the worldwide market more competitive and drive down prices.
The developers of givosiran announced the European Commission (EC) has granted the drug marketing authorisation based on results of the Phase III ENVISION trial.
